US Archives - Page 51 of 80 - European Medical Journal

Rare Mutated Cells Found in Healthy Breasts

Even healthy breast tissue harbors rare populations of mutated epithelial cells, raising important questions about their role in breast cancer development.

Lung Abnormalities Hidden in Routine Abdominal CTs

In a recent study, researchers found that interstitial lung abnormalities (ILAs), early indicators of interstitial lung disease, were present in 1.7% of routine abdominal and thoracoabdominal CT scans from unselected patients.

Biologics Breakthrough: Trends in Juvenile Arthritis Over 20 Years

The treatment landscape for juvenile idiopathic arthritis (JIA) has shifted significantly over the past two decades, according to a new study analyzing DMARD (disease-modifying antirheumatic drug) utilization among commercially insured children in the United States from 2001 to 2022.

High Fitness Cuts Dementia Risk By 35%

A new study in the UK Biobank suggests that high cardiorespiratory fitness (CRF) can significantly reduce dementia risk and delay its onset, even in individuals with a genetic predisposition to the condition.

The Psoriasis-Cancer Link: Surprising Study Findings

A significant risk associated with immune checkpoint inhibitors (ICIs), a class of cancer therapies, has been identified in a new study.

High-Dose Vitamin C Improves Survival in Pancreatic Cancer

A randomized clinical trial has revealed that pharmacological ascorbate (high-dose intravenous vitamin C) improves survival outcomes for patients with metastatic pancreatic cancer, a disease with notoriously low 5-year survival rates.

1 in 20 Adults Hospitalized After RSV Diagnosis

Respiratory syncytial virus (RSV) is a significant health concern for adults, contributing to thousands of hospitalizations annually.

Inebilizumab Targets IgG4 Disease Flares

Inebilizumab, a CD19+ B-cell depleting therapy, can reduce flares and promote remission in patients with IgG4-related disease (IgG4-RD) according to the results of a new Phase III clinical trial.

CRISPR Study Reveals Novel Rheumatoid Arthritis Targets: ACR24

Novel molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at the ACR Convergence 2024 in Washington, D.C.

Nipocalimab In Phase II Sjögren’s Disease Trial Results: ACR24

Data from the DAHLIAS Phase II was presented at ACR Convergence 2024 in Washington, D.C., as part of an abstract plenary session, sharing efficacy and safety of nipocalimab in treating primary Sjögren’s disease.